)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Pharma giants have already started work on different formulations and combination therapies of their existing molecules
Non-Covid revenues are back to 80% of Jan levels. Some expect demand to be 1.2 times pre-Covid level by Diwali
Modi's Independence Day speech focused on areas such as health and infra for a self-reliant New India. The first of a three-part series looks at the implications of the proposed Digital Health Mission
FAQs for clinical management prepared by AIIMS and MoHFW says evidence for Favipiravir is weak
The pandemic pushes pharma companies to look at drugs that held promise in transitioning to over the counter segment
Funding Covid-related research now included in CSR spends
India commands 40 per cent of global capacity for vaccines which is estimated at 5.7 billion doses
Expert group preparing the list also in touch with both local and MNC vaccine makers
The provisions of this policy shall apply to the entities involved in the NDHM and those who are a part of the NDHE
Russia reached out to India, players are open to collaborate but seek clarity on data
Major therapy areas show decline or low single-digit growth
Health care experts said it was about time the government set the ball rolling for scaling up manufacturing because there would not be much time left after the world had a vaccine candidate
Total income during the quarter fell by 47 per cent to Rs 610 crore
License agreement of Fortis, SRL brands expire in 2021
The vaccine candidate is in phase 1/2a clinical trials
Zydus plans to supply large quantities of the injectable drug in the market soon
Do these changes augur well for the future business growth plans? Analysts think so
A person close to the development said that of the various vaccine candidates under development now globally and in India, it is not yet clear how many shots would be required for each one
Will conduct clincial trials on anti-parasitic drug they claim is more effective than remdesivir
Companies wait for government orders as top medical research group says health workers must get first inoculation